Complications of myeloma and its treatments

Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Gracheva MA et al. Leuk Lymphoma. 2015 Apr 24:1-35. [Epub ahead of print]. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Keller S et al. Leuk Res. 2015 Mar 28. pii: S0145-2126(15)00086-7. doi: 10.1016/j.leukres.2015.03.015. [Epub ahead of print]. Subcutaneous bortezomib in multiple myeloma patients induces similar…

Details
Journal, Library, Management of complications & side effects

Current treatments

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. Merz M et al. Haematologica. 2015 Apr 3. pii: haematol.2015.124347. [Epub ahead of print]. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Grövdal M et al. Bone Marrow Transplant. 2015 Apr 13.…

Details
Journal, Library

Major milestone reached for Myeloma UK Clinical Trial Network with publication of data from MUK one

Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed…

Details
News